Skip to main content
Oregon.gov Homepage

Antiviral Therapies

Provider Operations ManualManual para ProveedoresTest to Treat LocatorCOVID-19 Therapeutics Locator

Important Updates


Paxlovid
  • On July 6th, 2022, the FDA updated the EUA for Paxlovid to allow for pharmacist prescribing for individual patients with certain limitations.
    • With this recent change in the Paxlovid EUA, Oregon-licensed pharmacists now have liability immunity and scope of authority to prescribe Paxlovid under the 9th amendment of the Department of Health and Human Services Public Readiness and Emergency Preparedness Act (PREP). 
    • Pharmacy interns and technicians cannot prescribe Paxlovid under the PREP Act because the Paxlovid EUA only authorizes pharmacists to prescribe Paxlovid. 
    • Pharmacists must adhere to the EUA and the PREP Act when prescribing Paxlovid, including all documentation and patient follow-up required under the EUA and PREP Act.
  • Please review the Paxlovid Rebound document.
  • If you requested Renal Paxlovid, but did not receive it, you might be allocated supplemental Paxlovid. Please review the guidance on renal dosing for Paxlovid.

 

General

  • For all questions or inquiries, please email us at OHA.therapeutics@odhsoha.oregon.gov
  • For additional federal updates, shelf-life extensions, and more, please visit the ASPR webpage and the ASPR COVID-19 Therapeutics Videos.
  • Please be sure to periodically review the CDC webpages regarding the list, and evidence used to update the list of underlying medical conditions associated with higher risk of severe COVID-19.


​​​Per the Oregon Medical Board (OMB) and Oregon Board of Pharmacy, dispensing of the oral COVID-19 antivirals Paxlovid and Molnupiravir can be done by using a pharmacy or by physicians or physician assistants who have been authorized by the Medical Board to dispense prescription medications. For more information, please refer to these guidelines provided by the OMB.

Paxlovid

  • ​Oral ​​treatment of mild-to-moderate COVID-19 illness
  • Must have a positive test within 5 days of symptoms, are at high risk for severe illness, and no other FDA-authorized treatment options due to medical conditions
  • Not recommended for patient with:
    • History of allergies to any component
    • Severe renal damage
    • Severe liver damage
    • Uncontrolled or undiagnosed HIV-infection
    • Multiple drug interactions including combined hormonal contraceptives and others 

​Lagevrio (molnupiravir)

  • ​​​Oral treatment of mild-to-moderate COVID-19 illness
  • Must have positive test with 5 days of symptoms, are high risk for severe illness, and no other FDA-authorized treatment options due to medical conditions
  • Safety Considerations:
    • Creation of strains with increased infectivity or virulence
    • Safety in pregnancy and potential fetal harm
    • Bone and cartilage toxicity (reason not authorized in <18 years)

All providers are now eligible to order both Paxlovid and Molnupiravir. OHA remains committed to equitable distribution of all therapeutics, however, due to supply fluctuations, OHA may not be able to fulfill 100% of the courses requested. 


​New Providers

Established Providers

  • Submit order requests directly in Health Partner Ordering Portal​ (HPoP)
  • Surveys are due on Wednesdays by 11:59 pm to be considered for the current weekly allocation. Surveys submitted after the due date will be considered for the next allocation cycle. 
  • Please refer to the below additional resources to assist in the ordering process. These can aslo be found on this page under the "Healthcare Provider Resources" section. 

​The Test to Treat (T2T) program connects eligible people who are at high risk of severe COVID-19, to treatments. These locations provide access for people to get tested, receive a prescription from a healthcare provider, and fill that prescription, all at one place or have your prescription sent to a nearby pharmacy. The Test to Treat (T2T) Locator helps you find places that provide these services. Keep in mind, many of the sites, including some Federally Qualified Health Centers (FQHCs), have telehealth capability. ​

The federal government has released the Test to Treat Locator to make it easier to find Test to Treat (T2T) locations. This locator connects folks to T2T sites. 

IMPORTANT: Please check the locator periodically as sites continue to be added. ​​

Weekly federal allocations
For specific information regarding sites that have therapeutics supply, please utilize the COVID-19 Therapeutics Locator. If you are an ordering provider, please check your email inbox for the weekly site allocation spreadsheet.

 Contact Us

oha.therapeutics@odhsoha.oregon.gov

 Healthcare Provider Resources

OHA Resources

Provider Operations Manual
Paxlovid EUA
Molnupiravir EUA
HPoP Direct Ordering
HPoP Profile Management
HPoP Reporting: Inventory & Utilization
Paxlovid Renal Adjustment
Paxlovid Rebound

COVID-19 Therapeutics Newsletters

July 2022
June 2022

Webinars for Providers

August 19, 2021 - OHA COVID-19 Senior Health Advisors Dawn Maunter, MD, MS and Shimi Sharief, MD, MPH
Watch the webinarDownload the slides
March 10, 2022 - OHA Outreach Coordinator Greg Desrosiers Sr. and Panelists
Watch the webinarDownload the slides
July 22, 2022 - OHA Outreach Coordinator Greg Desrosiers Sr. and Panelists
Watch the webinarDownload the slides

HHS Resources

Please email COVID-19Therapeutics@hhs.gov to request zoom links for the Weekly Federal COVID-19 Response webinars and office hours.
Reporting Utilization of COVID-19 Therapeutics
COVID-19 Therapeutics Locator

 Patient Resources

 Visit our treatments page